Rosiglitazone restrictions should be eased, says FDA advisory panel

Influenced by a recent RECORD readjudication showing lack of significant harm, a joint FDA advisory panel voted to keep rosiglitazone on the US market and to ease current prescribing restrictions but not remove them entirely.

Source: theHeart.org - June 7, 2013 Category: Cardiology Source Type: news